Excretion of anti-angiogenic proteins in patients with chronic allograft dysfunction

Eliza Moskowitz-Kassai, Lina MacKelaite, Jun Chen, Kaushal Patel, Darshana M. Dadhania, Steven S. Gross, Praveen Chander, Vera Delaney, Luqin Deng, Ligong Chen, Xiangqin Cui, Manikkam Suthanthiran, Michael S. Goligorsky

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background. We have recently documented the appearance of an anti-angiogenic peptide, endorepellin, in the urine of patients with chronic allograft dysfunction (CAD). Methods. Here, we analyzed using enzyme-linked immunosorbent assay the excretion of anti-angiogenic peptides endostatin, pigment epithelium-derived factor (PEDF) and Kruppel-like factor-2 (KLF-2), in healthy individuals, patients with stable graft function and patients with various degrees of CAD. Results. In healthy subjects and patients with CAD-0, endostatin, PEDF and KLF-2 excretions were at the level of detection. In contrast, there were significant differences between the patients with CAD-3 and CAD-0, CAD-1 and healthy controls for endostatin and CAD-0 versus CAD-3 for PEDF, but no differences in KLF-2 excretion. Receiver operating characteristic (ROC) curve analyses demonstrated a highly discriminative profile for all three biomarkers: the combination of these parameters offered 83% sensitivity and 90% specificity in distinguishing CAD-0 from CAD-1-3. The quality of these potential biomarkers of CAD was, however, highest in discriminating CAD status in biopsy-proven cases and dropped when CAD-0 was diagnosed based on clinical criteria.Conclusions.In conclusion, these findings indicate the diagnostic potential of urinary detection of endostatin, PEDF and to lesser degree KLF-2 and suggest a mechanistic role played by anti-angiogenic substances in the developing vasculopathy and vascular rarefaction in patients with CAD.

Original languageEnglish
Pages (from-to)494-497
Number of pages4
JournalNephrology Dialysis Transplantation
Volume27
Issue number2
DOIs
Publication statusPublished - 1 Feb 2012
Externally publishedYes

Fingerprint

Angiogenic Proteins
Allografts
Kruppel-Like Transcription Factors
Endostatins
Biomarkers

Keywords

  • endostatin
  • Kruppel-like factor 2
  • pigment epithelium-derived factor

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Moskowitz-Kassai, E., MacKelaite, L., Chen, J., Patel, K., Dadhania, D. M., Gross, S. S., ... Goligorsky, M. S. (2012). Excretion of anti-angiogenic proteins in patients with chronic allograft dysfunction. Nephrology Dialysis Transplantation, 27(2), 494-497. https://doi.org/10.1093/ndt/gfr638

Excretion of anti-angiogenic proteins in patients with chronic allograft dysfunction. / Moskowitz-Kassai, Eliza; MacKelaite, Lina; Chen, Jun; Patel, Kaushal; Dadhania, Darshana M.; Gross, Steven S.; Chander, Praveen; Delaney, Vera; Deng, Luqin; Chen, Ligong; Cui, Xiangqin; Suthanthiran, Manikkam; Goligorsky, Michael S.

In: Nephrology Dialysis Transplantation, Vol. 27, No. 2, 01.02.2012, p. 494-497.

Research output: Contribution to journalArticle

Moskowitz-Kassai, E, MacKelaite, L, Chen, J, Patel, K, Dadhania, DM, Gross, SS, Chander, P, Delaney, V, Deng, L, Chen, L, Cui, X, Suthanthiran, M & Goligorsky, MS 2012, 'Excretion of anti-angiogenic proteins in patients with chronic allograft dysfunction', Nephrology Dialysis Transplantation, vol. 27, no. 2, pp. 494-497. https://doi.org/10.1093/ndt/gfr638
Moskowitz-Kassai E, MacKelaite L, Chen J, Patel K, Dadhania DM, Gross SS et al. Excretion of anti-angiogenic proteins in patients with chronic allograft dysfunction. Nephrology Dialysis Transplantation. 2012 Feb 1;27(2):494-497. https://doi.org/10.1093/ndt/gfr638
Moskowitz-Kassai, Eliza ; MacKelaite, Lina ; Chen, Jun ; Patel, Kaushal ; Dadhania, Darshana M. ; Gross, Steven S. ; Chander, Praveen ; Delaney, Vera ; Deng, Luqin ; Chen, Ligong ; Cui, Xiangqin ; Suthanthiran, Manikkam ; Goligorsky, Michael S. / Excretion of anti-angiogenic proteins in patients with chronic allograft dysfunction. In: Nephrology Dialysis Transplantation. 2012 ; Vol. 27, No. 2. pp. 494-497.
@article{e9395f56345d4fba97d8c96fd3163ae6,
title = "Excretion of anti-angiogenic proteins in patients with chronic allograft dysfunction",
abstract = "Background. We have recently documented the appearance of an anti-angiogenic peptide, endorepellin, in the urine of patients with chronic allograft dysfunction (CAD). Methods. Here, we analyzed using enzyme-linked immunosorbent assay the excretion of anti-angiogenic peptides endostatin, pigment epithelium-derived factor (PEDF) and Kruppel-like factor-2 (KLF-2), in healthy individuals, patients with stable graft function and patients with various degrees of CAD. Results. In healthy subjects and patients with CAD-0, endostatin, PEDF and KLF-2 excretions were at the level of detection. In contrast, there were significant differences between the patients with CAD-3 and CAD-0, CAD-1 and healthy controls for endostatin and CAD-0 versus CAD-3 for PEDF, but no differences in KLF-2 excretion. Receiver operating characteristic (ROC) curve analyses demonstrated a highly discriminative profile for all three biomarkers: the combination of these parameters offered 83{\%} sensitivity and 90{\%} specificity in distinguishing CAD-0 from CAD-1-3. The quality of these potential biomarkers of CAD was, however, highest in discriminating CAD status in biopsy-proven cases and dropped when CAD-0 was diagnosed based on clinical criteria.Conclusions.In conclusion, these findings indicate the diagnostic potential of urinary detection of endostatin, PEDF and to lesser degree KLF-2 and suggest a mechanistic role played by anti-angiogenic substances in the developing vasculopathy and vascular rarefaction in patients with CAD.",
keywords = "endostatin, Kruppel-like factor 2, pigment epithelium-derived factor",
author = "Eliza Moskowitz-Kassai and Lina MacKelaite and Jun Chen and Kaushal Patel and Dadhania, {Darshana M.} and Gross, {Steven S.} and Praveen Chander and Vera Delaney and Luqin Deng and Ligong Chen and Xiangqin Cui and Manikkam Suthanthiran and Goligorsky, {Michael S.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1093/ndt/gfr638",
language = "English",
volume = "27",
pages = "494--497",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Excretion of anti-angiogenic proteins in patients with chronic allograft dysfunction

AU - Moskowitz-Kassai, Eliza

AU - MacKelaite, Lina

AU - Chen, Jun

AU - Patel, Kaushal

AU - Dadhania, Darshana M.

AU - Gross, Steven S.

AU - Chander, Praveen

AU - Delaney, Vera

AU - Deng, Luqin

AU - Chen, Ligong

AU - Cui, Xiangqin

AU - Suthanthiran, Manikkam

AU - Goligorsky, Michael S.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Background. We have recently documented the appearance of an anti-angiogenic peptide, endorepellin, in the urine of patients with chronic allograft dysfunction (CAD). Methods. Here, we analyzed using enzyme-linked immunosorbent assay the excretion of anti-angiogenic peptides endostatin, pigment epithelium-derived factor (PEDF) and Kruppel-like factor-2 (KLF-2), in healthy individuals, patients with stable graft function and patients with various degrees of CAD. Results. In healthy subjects and patients with CAD-0, endostatin, PEDF and KLF-2 excretions were at the level of detection. In contrast, there were significant differences between the patients with CAD-3 and CAD-0, CAD-1 and healthy controls for endostatin and CAD-0 versus CAD-3 for PEDF, but no differences in KLF-2 excretion. Receiver operating characteristic (ROC) curve analyses demonstrated a highly discriminative profile for all three biomarkers: the combination of these parameters offered 83% sensitivity and 90% specificity in distinguishing CAD-0 from CAD-1-3. The quality of these potential biomarkers of CAD was, however, highest in discriminating CAD status in biopsy-proven cases and dropped when CAD-0 was diagnosed based on clinical criteria.Conclusions.In conclusion, these findings indicate the diagnostic potential of urinary detection of endostatin, PEDF and to lesser degree KLF-2 and suggest a mechanistic role played by anti-angiogenic substances in the developing vasculopathy and vascular rarefaction in patients with CAD.

AB - Background. We have recently documented the appearance of an anti-angiogenic peptide, endorepellin, in the urine of patients with chronic allograft dysfunction (CAD). Methods. Here, we analyzed using enzyme-linked immunosorbent assay the excretion of anti-angiogenic peptides endostatin, pigment epithelium-derived factor (PEDF) and Kruppel-like factor-2 (KLF-2), in healthy individuals, patients with stable graft function and patients with various degrees of CAD. Results. In healthy subjects and patients with CAD-0, endostatin, PEDF and KLF-2 excretions were at the level of detection. In contrast, there were significant differences between the patients with CAD-3 and CAD-0, CAD-1 and healthy controls for endostatin and CAD-0 versus CAD-3 for PEDF, but no differences in KLF-2 excretion. Receiver operating characteristic (ROC) curve analyses demonstrated a highly discriminative profile for all three biomarkers: the combination of these parameters offered 83% sensitivity and 90% specificity in distinguishing CAD-0 from CAD-1-3. The quality of these potential biomarkers of CAD was, however, highest in discriminating CAD status in biopsy-proven cases and dropped when CAD-0 was diagnosed based on clinical criteria.Conclusions.In conclusion, these findings indicate the diagnostic potential of urinary detection of endostatin, PEDF and to lesser degree KLF-2 and suggest a mechanistic role played by anti-angiogenic substances in the developing vasculopathy and vascular rarefaction in patients with CAD.

KW - endostatin

KW - Kruppel-like factor 2

KW - pigment epithelium-derived factor

UR - http://www.scopus.com/inward/record.url?scp=84863134826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863134826&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfr638

DO - 10.1093/ndt/gfr638

M3 - Article

VL - 27

SP - 494

EP - 497

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 2

ER -